Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 3
2016 2
2017 2
2018 2
2020 2
2021 5
2022 1
2023 2
2024 2
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P. Marchetti C, et al. Among authors: vertechy l. Cancer Treat Rev. 2016 Jan;42:41-6. doi: 10.1016/j.ctrv.2015.10.011. Epub 2015 Nov 10. Cancer Treat Rev. 2016. PMID: 26559739 Review.
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.
Marchetti C, Fagotti A, Fruscio R, Cassani C, Incorvaia L, Perri MT, Sassu CM, Camnasio CA, Giudice E, Minucci A, Seca M, Arbustini E, Vertechy L, De Bonis M, Boccia SM, Giannarelli D, Salutari V, Distefano M, Ferrandina MG, Nero C, Musacchio L, Russo A, Scambia G, Lorusso D. Marchetti C, et al. Among authors: vertechy l. ESMO Open. 2025 Apr;10(4):104533. doi: 10.1016/j.esmoop.2025.104533. Epub 2025 Apr 1. ESMO Open. 2025. PMID: 40174507 Free PMC article.
Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
Boccia SM, Sassu CM, Ergasti R, Vertechy L, Apostol AI, Palluzzi E, Fagotti A, Scambia G, Marchetti C. Boccia SM, et al. Among authors: vertechy l. Drug Des Devel Ther. 2024 Jun 7;18:2021-2032. doi: 10.2147/DDDT.S451223. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38863768 Free PMC article. Review.
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.
Giudice E, Salutari V, Sassu CM, Ghizzoni V, Carbone MV, Vertechy L, Fagotti A, Scambia G, Marchetti C. Giudice E, et al. Among authors: vertechy l. Expert Rev Anticancer Ther. 2024 Aug;24(8):649-655. doi: 10.1080/14737140.2024.2362178. Epub 2024 Jun 11. Expert Rev Anticancer Ther. 2024. PMID: 38861580 Free article. Review.
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.
Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, Bracchi C, Tomao F, Di Donato V, De Felice F, Monti M, Muzii L, Benedetti Panici P. Musella A, et al. Among authors: vertechy l. Chemotherapy. 2017;62(2):111-120. doi: 10.1159/000448942. Epub 2016 Oct 29. Chemotherapy. 2017. PMID: 27794568 Review.
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P. Musella A, et al. Among authors: vertechy l. Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23. Cancer Treat Rev. 2018. PMID: 29605737 Review.
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.
Marchetti C, Palaia I, Giorgini M, De Medici C, Iadarola R, Vertechy L, Domenici L, Di Donato V, Tomao F, Muzii L, Benedetti Panici P. Marchetti C, et al. Among authors: vertechy l. Onco Targets Ther. 2014 Jul 10;7:1223-36. doi: 10.2147/OTT.S40947. eCollection 2014. Onco Targets Ther. 2014. PMID: 25031539 Free PMC article. Review.
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence.
Loverro M, Marchetti C, Salutari V, Giannarelli D, Vertechy L, Capomacchia FM, Caricato C, Campitelli M, Panico C, Avesani G, Cocciolillo F, Rosati A, Scambia G, Fagotti A. Loverro M, et al. Among authors: vertechy l. ESMO Open. 2025 Feb;10(2):104119. doi: 10.1016/j.esmoop.2024.104119. Epub 2025 Jan 17. ESMO Open. 2025. PMID: 39826478 Free PMC article.
30 results